Exclusive License Agreement and Patent Assignment Agreement (Details Narrative) - License Agreement [Member] - USD ($) |
May 03, 2022 |
Jul. 18, 2019 |
|---|---|---|
| Non-refundable Payment | $ 400,000 | |
| Additional Payments Payable Upon Achievement Of Certain Milestones Under Agreement By Related Party | 24,000,000.0 | |
| Payment Due Following Commencement Of First Phase Iii Clinical Trial Of Brilacidin | 1,000,000.0 | |
| Payment Due Upon Filing Of A Marketing Approval Application | $ 1,000,000.0 | |
| FCCDC's third-party license of broad-spectrum anti-fungals | $ 18,000 |